COMMUNIQUÉS West-GlobeNewswire

T2 Biosystems Announces Third Quarter 2024 Financial Results
14/11/2024
Achieved 34% quarterly revenue growth compared to the prior year period LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis- [...]
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
14/11/2024
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided [...]
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
14/11/2024
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number [...]
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
14/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes [...]
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
14/11/2024
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated [...]
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update
14/11/2024
Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene ® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy [...]
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
14/11/2024
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025 Approximately $264 million in cash, cash equivalents and investments [...]
Ascendis Pharma Reports Third Quarter 2024 Financial Results
14/11/2024
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA [...]
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
13/11/2024
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in Q3 of 2023 and 28.5% in [...]
UPDATE - Canada’s First Precision Health and Longevity Summit 2024: Uniting Global Leaders on November 15-16
13/11/2024
Unlocking the Future of Healthcare: Pioneering Strategies and Global Collaboration to Enhance Longevity and Health Outcomes for All Canadians CALGARY, Alberta, Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Precision Health and [...]
Calidi Biotherapeutics Announces Proposed Public Offering
13/11/2024
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
13/11/2024
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Jasper Therapeutics to Participate at Upcoming Investor Conferences
13/11/2024
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
13/11/2024
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for [...]
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
13/11/2024
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2024 on [...]
Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
13/11/2024
– Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH – – Kriya plans to evaluate KRIYA-497, a one-time intramuscular gene therapy [...]
Natural Alternatives International, Inc. Announces 2025 Q1 Results
13/11/2024
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]
Telix ADSs Commence Trading on Nasdaq
13/11/2024
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq [...]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data, [...]

Pages